Vortioxetine is indicated for the treatment of moderate to severe major depressive episodes. The clinical action of Vortioxetine is mediated by selective blockade of serotonin reuptake and modulation of serotonin receptor activity. Although Vortioxetine appears to be more effective than placebo in the management of major depression, its place in the treatment of this pathology is unclear. Indeed, the lack of randomized controlled trials comparing Vortioxetine with first-line treatments for major depression (such as selective serotonin reuptake inhibitors) severely limits the interpretation of currently available data in the literature. However, given its potential pro-cognitive action, Vortioxetine may therefore be a treatment of choice in ...
The article provides an experience of use of the new antidepressant with the precognitive action – V...
none7siVortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 fo...
Introduction: Inadequate treatment response and emotional blunting are common challenges with select...
Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity...
Vortioxetine is a new multimodal action antidepressant with two types of action: serotonin transport...
Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity...
Background: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transport...
Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major...
Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder ...
The pharmacological treatment of depression is often hampered by side-effects and unsatisfactory res...
AbstractVortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), i...
Background: Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important...
Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depres...
Depression and cerebrovascular atherosclerosis often occur in comorbidity showing neuropsychological...
Major depressive disorder, a common debilitating illness, is one of the leading causes of disability...
The article provides an experience of use of the new antidepressant with the precognitive action – V...
none7siVortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 fo...
Introduction: Inadequate treatment response and emotional blunting are common challenges with select...
Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity...
Vortioxetine is a new multimodal action antidepressant with two types of action: serotonin transport...
Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity...
Background: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transport...
Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major...
Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder ...
The pharmacological treatment of depression is often hampered by side-effects and unsatisfactory res...
AbstractVortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), i...
Background: Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important...
Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depres...
Depression and cerebrovascular atherosclerosis often occur in comorbidity showing neuropsychological...
Major depressive disorder, a common debilitating illness, is one of the leading causes of disability...
The article provides an experience of use of the new antidepressant with the precognitive action – V...
none7siVortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 fo...
Introduction: Inadequate treatment response and emotional blunting are common challenges with select...